Entera Bio(ENTX) - 2023 Q3 - Quarterly Report

WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission file number: 001-38556 ENTERA BIO LTD. (Exact name of Registrant as specified in its charter) | Israel | Not applicable | | --- | --- | | (State or oth ...